CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?
Transl Lung Cancer Res
.
2019 Dec;8(Suppl 4):S464-S467.
doi: 10.21037/tlcr.2019.12.26.
Authors
Jose Carlos Benitez
1
,
Jordi Remon
2
,
Benjamin Besse
1
3
Affiliations
1
Gustave Roussy, Department of Cancer Medicine, Villejuif, France.
2
Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain.
3
Paris-Sud University Bicetre, Orsay, France.
PMID:
32038939
PMCID:
PMC6987362
DOI:
10.21037/tlcr.2019.12.26
No abstract available
Publication types
Editorial
Comment